BioCentury
ARTICLE | Clinical News

Clinical hold for Arrowhead's HBV therapy

November 9, 2016 11:27 PM UTC

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) fell $1.91 (31%) to $4.20 on Wednesday after it said FDA placed a clinical hold on the Phase IIb Heparc-2004 trial of short interfering RNA therapy ARC-520 to treat HBV.

The trial is evaluating ARC-520 in combination with entecavir or tenofovir in up to 12 hepatitis B e antigen (HBeAg)-positive patients with chronic HBV infection...